INTRODUCTION {#s1}
============

Lung cancer is the most common cancer in men and the leading cause of cancer death in women \[[@R1]\]. The 5-year relative survival of lung cancer is currently 18% \[[@R2]\]. Especially, lung cancer diagnosed in China comprises about 33-50% of the global incidence burden. For lung cancer, 733,300 new cases and 432,400 deaths were estimated to appear in China in 2015 \[[@R3]\]. Cyclophosphamide (CTX) has been widely used to block the progression of lung cancer in clinic \[[@R4]\]. However, CTX generally causes severe acute toxicities like myelosuppression \[[@R5]\]. Once myelosuppression appears, patients are more likely to suffer from infection. Currently, protecting patients from CTX-induced myelosuppression is a main challenge in lung cancer treatment.

Nowadays, colony-stimulating factor, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor are the main drugs in treating myelosuppression \[[@R6], [@R7]\]. However, these drugs can lead to lung injury, splenic rupture and vascular events, and they even promote cancer development and metastasis \[[@R8], [@R9]\]. As a traditional Chinese medicine, Shuanghuang Shengbai (SHSB) granule has been widely used in clinic for decades in China \[[@R10]\]. It can increase white blood cells (WBCs) and cure myelosuppression, whereas it cannot cause obvious adverse effect or cancer progression \[[@R11], [@R12]\]. Reportedly, SHSB granule can enhance the epidermal growth factor receptor signaling pathway in bone marrow and the Notch signaling pathway in bone marrow nuclear cells \[[@R13], [@R14]\]. SHSB granule can reduce the percentage of bone marrow cells (BMCs) in G0/G1 phase and increase the proliferation index of BMCs via up-regulating CDK4, CDK6 and cyclin D1 \[[@R15]\]. Also, it promotes the transformation of hematopoietic stem cells from G0/G1 phase to S phase via up-regulating c-Myc, cell division cycle 25A, Rb, pRb and E2F in bone marrow nuclear cells \[[@R10]\]. On the contrary, it inhibits the proliferation of tumor cells in an opposite way \[[@R10], [@R15]\].

Reportedly, WBCs are mainly differentiated from bone marrow hematopoietic stem cells (BMHSCs; e.g. CD34^+^SCA1^+^ BMHSCs). Lung cancer stem cells (LCSCs) are responsible for the initiation, progression, metastasis and relapse of lung cancers (e.g. SP^+^ LCSCs, CD24^+^IGF1R^+^ LCSCs and CD133^+^ LCSCs) \[[@R16], [@R17]\]. Therefore, the proliferation and numbers of BMHSCs and LCSCs are critical for myelosuppression and lung cancer. As a kind of non-coding RNAs, microRNAs play crucial roles in cell proliferation via regulating the expression of target genes post-transcriptionally \[[@R18], [@R19]\]. However, the effect of SHSB granule on LCSCs and BMHSCs and the corresponding mechanism at microRNA level are still unclear.

In the present study, nude mice with lung cancer were treated with physiological saline, CTX, or CTX + SHSB granule. Then, LCSCs ratio and BMHSCs ratio were determined. Microarray analysis was performed to study the microRNA profiling of LCSCs and BMHSCs. MicroRNA expressions were further validated using quantitative real time-polymerase chain reaction (qRT-PCR). Our results might shed light on the mechanism and therapeutic targets of SHSB granule in curing myelosuppression from the aspect of microRNAs.

RESULTS {#s2}
=======

Tumor mass and general blood indexes {#s2_1}
------------------------------------

Tumor masses in CTX and CTX+SHSB groups were significantly smaller than that in control group (4-d, 6-d, 8-d and 10-d; P\<0.05; Figure [1A](#F1){ref-type="fig"}). When compared with control group, WBCs were significantly decreased after CTX injection (4-d, 6-d and 8-d; P\<0.05; Figure [1B](#F1){ref-type="fig"}). However, SHSB treatment reversed the CTX-induced decline in WBCs, and the number of WBCs was completely recovered 10 days after SHSB treatment (10-d; Figure [1B](#F1){ref-type="fig"}). Besides, red blood cells and platelets in the three groups were similar (4-d, 6-d, 8-d and 10-d; Figure [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}).

![Effects of CTX and SHSB granule on nude mice with lung cancer\
**(A)** Tumor mass. **(B)** White blood cells. **(C)** Red blood cells. **(D)** Platelets. **(E)** Proliferation index of lung cancer cells. **(F)** Proliferation index of BMCs. **(G)** Ratio of SP^+^ LCSCs. **(H)** Ratio of CD24^+^IGF1R^+^ LCSCs. **(I)** Ratio of CD133^+^ LCSCs. **(J)** Ratio of CD34^+^SCA1^+^ BMHSCs. \#: P\<0.05 when compared with control group. \*: P\<0.05 when compared with CTX group. CTX: cyclophosphamide; SHSB: Shuanghuang Shengbai; BMCs: bone marrow cells; LCSCs: lung cancer stem cells; BMHSCs: bone marrow hematopoietic stem cells. For all these tests, N=9.](oncotarget-08-62154-g001){#F1}

Cell cycle and proliferation index {#s2_2}
----------------------------------

Proliferation index of lung cancer cells in CTX+SHSB group was significantly lower than that in CTX and control groups (4-d, 6-d, 8-d and 10-d; P\<0.05; Figure [1E](#F1){ref-type="fig"}).

Moreover, the proliferation index of BMCs in CTX group was first significantly decreased (4-d; P\<0.05) and then increased (6-d, 8-d and 10-d; P\<0.05; Figure [1F](#F1){ref-type="fig"}) in comparison with that in control group. In contrast, the proliferation index of BMCs in CTX+SHSB group was remarkably higher than that in CTX and control groups (8-d and 10-d; P\<0.05; Figure [1F](#F1){ref-type="fig"}).

Ratio of stem cells {#s2_3}
-------------------

SP^+^ LCSCs ratio was significantly declined after CTX injection and further declined after CTX+SHSB treatment (8-d and 10-d; P\<0.05; Figure [1G](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). CD24^+^IGF1R^+^ LCSCs ratio in control and CTX groups were similar, whereas it was remarkably decreased after CTX+SHSB treatment (4-d, 6-d, 8-d and 10-d; P\<0.05; Figure [1H](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). In addition, CD133^+^ LCSCs ratio was declined after CTX or CTX+SHSB treatment (4-d and 10-d; P\<0.05; Figure [1I](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

In comparison with control group, CD34^+^SCA1^+^ BMHSCs ratio in CTX group was first decreased (4-d and 6-d; P\<0.05), then increased (8-d; P\<0.05), and finally decreased (10-d; P\<0.05) after CTX injection (Figure [1J](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). In contrast, CD34^+^SCA1^+^ BMHSCs ratio in CTX+SHSB group was remarkably higher than that in CTX group and constantly increased along with the treating time (4-d, 6-d, 8-d and 10-d; P\<0.05; Figure [1J](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). These results were consistent with the results of proliferation index of BMCs (Figure [1F](#F1){ref-type="fig"}).

MicroRNA microarray analysis {#s2_4}
----------------------------

MicroRNAs isolated from SP^+^ LCSCs (8-d) and CD34^+^SCA1^+^ BMHSCs (6-d) were analyzed using microarray (miRCURY™ LNA Array, version: 16.0; Figure [2A](#F2){ref-type="fig"}). Based on Volcano Plot filtering (Figure [2B](#F2){ref-type="fig"}), 49, 5 and 49 DEmiRNAs in LCSCs were found between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure [2C](#F2){ref-type="fig"}). A total of 278, 45 and 234 DEmiRNAs in BMHSCs were identified between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure [2C](#F2){ref-type="fig"}). Furthermore, ANOVA analysis identified 45 DEmiRNAs (in LCSCs) and 343 DEmiRNAs (in BMHSCs) between the three groups (Table [1](#T1){ref-type="table"}).

![Microarray analysis of microRNAs in LCSCs and BMHSCs\
**(A)** Heat-maps of microRNAs in LCSCs and BMHSCs in the three groups. **(B)** Volcano plot filtering and DEmiRNAs screening. **(C)** Hierarchical clustering of DEmiRNAs between CTX and CTX+SHSB groups. LCSCs: lung cancer stem cells; BMHSCs: bone marrow hematopoietic stem cells; DEmiRNAs: differentially expressed microRNAs; CTX: cyclophosphamide; SHSB: Shuanghuang Shengbai.](oncotarget-08-62154-g002){#F2}

###### DEmiRNAs in LCSCs and BMHSCs

  Cell         DEmiRNA                                                                                                
  ------------ ----------------------------- --------------------------- ----------------------- -------------------- -----------------------
  **LCSCs**    mmu-miR-3095-3p               mmu-miR-669a/o-3p           mmu-miR-466f            mmu-miR-431          mmu-miR-3081\*
               mmu-miR-466a/p-5p             mmu-miR-379                 mmu-miR-1897-5p         mmu-miR-488\*        mcmv-miR-M23-2\*
               **mmu-miR-32\***              mmu-miR-3065\*              mmu-miR-194-2\*         mmu-miR-1192         mmu-miR-675-5p
               mmu-miR-466a-5p               **mmu-miR-466i-5p**         mmu-miR-881\*           mmu-miR-106b\*       mmu-miR-881
               **mmu-miR-34c\***             mmu-miR-3071                **mmu-miR-122\***       mmu-miR-1187         mmu-miR-291a-5p
               mmu-miR-3082-5p               mmu-miR-669k\*              mmu-miR-669d            mmu-miR-3067         mmu-miR-669o-5p
               mmu-miR-195\*                 mmu-miR-669e                mmu-miR-466c-5p         mcmv-miR-m01-2       mmu-miR-669l
               mmu-miR-669f-5p               mmu-miR-3078\*              mmu-miR-466b/o-5p       mmu-miR-669n         **mmu-miR-541\***
               **mmu-miR-669c**              mmu-miR-706                 mmu-miR-466e-5p         mmu-miR-669p\*       mmu-miR-221\*
  **BMHSCs**   mmu-miR-3103\*                mmu-miR-194                 mmu-miR-669l\*          mmu-miR-669m-3p      mmu-miR-19a
               mmu-miR-434-3p                mmu-miR-32\*                mmu-miR-192             mmu-miR-1971         mmu-miR-126-5p
               mmu-miR-467d\*                mmu-miR-145\*               mmu-miR-99a             mmu-miR-677          mmu-miR-215
               mmu-miR-467b\*                mmu-miR-762                 mmu-miR-374             mmu-miR-350          mmu-miR-681
               mmu-miR-714                   mmu-miR-499                 mmu-let-7c              mmu-miR-16-2\*       mmu-miR-133b
               mmu-miR-466i-3p               mmu-miR-702                 mmu-miR-466a/e-3p       mmu-miR-196a-1\*     mmu-miR-291b-3p
               mmu-miR-883a-5p               mmu-miR-329\*               mmu-miR-136             mmu-miR-675-5p       mmu-miR-1962
               mmu-miR-3090\*                mmu-miR-376a                mmu-miR-466f-3p         mmu-miR-411          mmu-miR-3098-3p
               mmu-miR-669d-2\*              mmu-miR-7b\*                mmu-miR-142-5p          mmu-miR-434-5p       mmu-miR-146a
               mmu-miR-100                   mmu-miR-224                 mmu-miR-1946b           mmu-miR-1b-5p        mmu-miR-496\*
               mmu-miR-466m-3p               mmu-miR-466a/b/c/e/p/n-3p   mmu-miR-3086-3p         mmu-let-7d\*         mmu-miR-300
               mmu-miR-721                   mmu-miR-466n-3p             mmu-miR-29a\*           mmu-miR-1247         mmu-miR-345-5p
               mmu-miR-467c\*                **mmu-miR-144**             mmu-miR-770-3p          mmu-miR-1a-1\*       mmu-miR-465c-5p
               mmu-miR-1900                  mmu-miR-2861                mmu-miR-34c\*           mmu-miR-154\*        mmu-miR-138-2\*
               mmu-miR-3095-3p               mmu-miR-493                 mmu-miR-22              mmu-miR-101a         mmu-miR-1249
               mmu-miR-23a\*                 mmu-miR-668\*               mmu-miR-296-3p          mmu-miR-106a         mmu-miR-877
               mcmv-miR-m88-1                mmu-miR-470                 mmu-miR-29b             mmu-miR-24-2\*       mmu-miR-21\*
               mmu-miR-3064-5p               mmu-miR-146b                mmu-miR-669h-3p         mmu-miR-185\*        mmu-miR-669m/466m-5p
               mmu-miR-490-3p                mmu-miR-292-5p              mmu-miR-466l-3p         mmu-miR-1931         mmu-miR-703
               mmu-miR-24                    mmu-miR-5097                mmu-miR-152             mmu-miR-325\*        mmu-miR-140
               mmu-miR-467e\*                mmu-miR-145                 mmu-miR-290-3p          mmu-miR-344g-5p      mmu-miR-15a
               mmu-miR-127                   mmu-miR-19b                 mmu-miR-3104-5p         mmu-miR-128-2\*      mmu-miR-328
               mmu-miR-467a\*                mmu-miR-194-2\*             mmu-miR-1187            mmu-miR-149          mmu-miR-378
               mmu-miR-29c                   mghv-miR-M1-2-3p            mmu-miR-125a-3p         mmu-miR-706          mmu-miR-450a
               mmu-miR-297a\*/c\*/-297b-3p   mmu-miR-92a-2\*             mmu-miR-132\*           mmu-miR-1194         mmu-miR-339-5p
               mmu-miR-138-1\*               mmu-miR-218                 mmu-miR-224\*           mmu-miR-365-2\*      mmu-miR-1949
               mghv-miR-M1-5                 mmu-miR-669i                mmu-miR-503\*           mghv-mir-M1-1\*      **mmu-miR-142-3p**
               mmu-miR-466g                  mmu-miR-3057-5p             mmu-miR-216a\*          mmu-miR-582-3p       mmu-miR-300\*
               mmu-miR-27b                   mmu-miR-574-3p              mmu-miR-290-5p          mmu-miR-3060\*       mmu-let-7e
               mmu-miR-669d\*/669d-2\*       mmu-miR-3097-5p             mmu-miR-678             mmu-miR-2139         mmu-miR-503
               mmu-miR-195\*                 mmu-miR-3078\*              mmu-miR-3073-3p         mmu-miR-30c-2\*      mmu-miR-1224
               mmu-miR-467f                  mghv-mir-M1-8\*             mmu-miR-199a-3p/-199b   mmu-miR-741          mmu-miR-196a-2\*
               mmu-miR-1982\*                mmu-miR-1839-5p             mmu-miR-669f-5p         mmu-miR-761          mmu-miR-3081\*
               mghv-miR-M1-7-3p              mmu-miR-1967                mmu-miR-344b\*          mmu-miR-466o-3p      mmu-miR-3072
               mmu-miR-669b\*                mmu-miR-466c-5p             mmu-miR-1935            mmu-miR-150          mmu-miR-34c
               mmu-let-7g                    mmu-miR-99b                 mmu-miR-208a-5p         mmu-miR-99b\*        mmu-miR-322
               mmu-miR-125a-5p               mmu-miR-467g                mmu-miR-3082-5p         mmu-miR-106b         mmu-miR-27a\*
               **mmu-miR-223**               mmu-miR-133a                mmu-miR-223\*           mmu-miR-1899         mmu-miR-1896
               mmu-miR-1892                  mmu-miR-468                 mmu-miR-3474            mmu-miR-3072\*       mmu-miR-379
               mmu-miR-465b-5p               mghv-mir-M1-2-5p            mmu-miR-344d-2\*        mmu-miR-1192         mmu-miR-1982.1/1982.2
               mmu-miR-669a-3-3p             mmu-miR-328\*               mmu-miR-466d-3p         mmu-miR-203          mmu-miR-423-5p
               mmu-miR-199b\*                mmu-miR-221                 mmu-miR-10b             mmu-miR-23b\*        mmu-miR-1927
               mmu-miR-882                   mmu-miR-491\*               mmu-miR-30b             mmu-miR-181d         mmu-miR-466f
               mmu-miR-341                   mmu-miR-378/378b            mmu-miR-669n            mmu-miR-1958         mmu-miR-93
               mmu-miR-125b-5p               mmu-miR-488                 mmu-miR-34b-5p          mmu-miR-466j         mmu-miR-193b
               mmu-miR-710                   mmu-miR-135a-1\*            mmu-miR-742             mmu-miR-214\*        mmu-miR-652
               mmu-miR-466a/p-5p             mmu-miR-712                 mmu-miR-3102            mmu-miR-511-3p       mmu-miR-3084
               mmu-let-7i                    mmu-miR-466d-5p             mmu-miR-874\*           mmu-miR-148b\*       mmu-miR-20a\*
               mmu-miR-298                   mmu-miR-546                 mmu-miR-466e-5p         mmu-miR-200c\*       mmu-miR-1957
               mmu-miR-1934                  mmu-miR-143                 mmu-miR-1193-3p         mmu-miR-365          mmu-miR-547\*
               mmu-miR-1981\*                mmu-miR-505-5p              mmu-miR-692             mmu-miR-331-5p       mmu-miR-669p\*
               **mmu-miR-669k\***            mmu-miR-196b\*              mmu-miR-669f-3p         mmu-miR-3101\*       mmu-miR-484
               mmu-miR-669e\*                mmu-miR-129-2-3p            mmu-miR-29c\*           mmu-miR-381          mmu-miR-301b
               mmu-miR-206                   mmu-miR-1a-2\*              mmu-miR-431\*           mmu-miR-194-1\*      mmu-miR-344\*
               mmu-miR-871-3p                mmu-miR-28\*                mmu-miR-377\*           mmu-miR-673-3p       mmu-miR-1839-3p
               mmu-miR-30d                   mmu-miR-344c\*              mmu-miR-139-5p          mmu-miR-539-3p       mmu-miR-669h-5p
               mmu-miR-1981                  mmu-miR-760-3p              mmu-miR-544-5p          mmu-miR-374/374c     mghv-miR-M1-13\*
               mmu-miR-155                   mmu-miR-181a                mmu-miR-325             mmu-miR-31           mmu-miR-181b
               mmu-miR-669e                  mmu-miR-466b/o-5p           mmu-miR-186\*           mghv-miR-M1-3        mmu-miR-509-5p
               mmu-miR-23a                   mmu-miR-199a-5p             mmu-miR-497             mmu-miR-669c\*       mmu-miR-1247\*
               mmu-miR-433                   mmu-miR-881                 mmu-miR-1188\*          mmu-miR-410          mmu-miR-378\*
               mmu-miR-425                   **mmu-miR-210**             mmu-miR-758\*           **mmu-miR-106b\***   mcmv-miR-m88-1\*
               mmu-miR-463                   mmu-miR-3069-3p             mmu-miR-615-3p          mmu-miR-671-3p       mmu-miR-128
               mmu-miR-669a/o-3p             mmu-miR-2136                mmu-miR-383\*           mmu-miR-490-5p       mmu-miR-3084\*
               mmu-miR-1929                  mmu-miR-196a                mmu-miR-342-3p          mmu-miR-335-5p       mmu-miR-878-5p
               mmu-miR-30e                   mmu-miR-499\*               mmu-miR-3067\*          mmu-miR-125b-2-3p    mmu-miR-205\*
               mmu-miR-466a-5p               mmu-miR-320                 mmu-miR-25\*            mmu-miR-3102-3p.2    mmu-miR-204\*
               mmu-let-7b                    mmu-miR-30c                 mmu-miR-500\*           mmu-miR-219-3p       
               mmu-miR-362-3p                mmu-miR-455\*               mmu-miR-3098-5p         mmu-miR-193          

DEmiRNAs in bold were confirmed using qRT-PCR. DEmiRNAs: differentially expressed microRNAs; LCSCs: lung cancer stem cells; BMHSCs: bone marrow hematopoietic stem cells; CTX: cyclophosphamide; SHSB: Shuanghuang Shengbai; ANOVA: analysis of variance; qRT-PCR: quantitative real time-polymerase chain reaction.

Confirmation of 12 DEmiRNAs {#s2_5}
---------------------------

QRT-PCR was performed to confirm the differential expression of 12 DEmiRNAs (Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). As shown in Figure [3](#F3){ref-type="fig"}, mmu-miR-32\* (Figure [3A](#F3){ref-type="fig"}), mmu-miR-466i-5p (Figure [3B](#F3){ref-type="fig"}) and mmu-miR-669c (Figure [3C](#F3){ref-type="fig"}) in SP^+^ LCSCs were significantly up-regulated after CTX treatment. These microRNAs were further up-regulated after CTX+SHSB treatment. These results demonstrated that CTX promoted the expression of these microRNAs in SP^+^ LCSCs, and SHSB further strengthened their expression.

###### Primers for miRNA qRT-PCR

  ---------------------------------------------------------------------------------------------
  miRNA         RT (Primer)                  PCR (Forward primer)        PCR (Reverse primer)
  ------------- ---------------------------- --------------------------- ----------------------
  mir-144       GTCGTATCCAGTGCAGGGTCCGAGG\   CGGCCGGTACAGTATAGATGA       GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCAGTACA                               

  mir-106b\*    GTCGTATCCAGTGCAGGGTCCGAGG\   AATGCCGCACTGTGGGTACT        GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCGCAGCA                               

  mir-669k\*    GTCGTATCCAGTGCAGGGTCCGAGG\   GCCCGGTGTGCATGTGTGTATAGTT   GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCGCACAC                               

  mir-142-3p    GTCGTATCCAGTGCAGGGTCCGAGG\   GCGCTGTAGTGTTTCCTACTT       GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCTCCATA                               

  mir-223       GTCGTATCCAGTGCAGGGTCCGAGG\   CCGCCCGTGTCAGTTTGTCAAAT     GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCTGGGGT                               

  mir-210       GTCGTATCCAGTGCAGGGTCCGAGG\   AATCCTGTGCGTGTGACAGC        GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCTCAGCC                               

  mir-32\*      GTCGTATCCAGTGCAGGGTCCGAGG\   CGCGCGGCCAATTTAGTGTGTGT     GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCAATATC                               

  mir-669C      GTCGTATCCAGTGCAGGGTCCGAGG\   CGCGCCATAGTTGTGTGTGGAT      GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCACACAC                               

  mir-466i-5p   GTCGTATCCAGTGCAGGGTCCGAGG\   CGCCCTGTGTGTGTGTGTG         GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCCACACA                               

  mir-122\*     GTCGTATCCAGTGCAGGGTCCGAGG\   CGCCCAAACGCCATTATCA         GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCTTAGTG                               

  mir-34C\*     GTCGTATCCAGTGCAGGGTCCGAGG\   GCCCAATCACTAACCACACA        GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCCCTGGC                               

  mir-541\*     GTCGTATCCAGTGCAGGGTCCGAGG\   ACACCCTGGCGAACACAGAATC      GTGCAGGGTCCGAGGT
                TATTCGCACTGGATACGACCAGTATG                               

  U6                                         CTCGCTTCGGCAGCACA           AACGCTTCACGAATTTGCGT
  ---------------------------------------------------------------------------------------------

**MiRNA:** microRNA; qRT-PCR: quantitative real time-polymerase chain reaction; RT: reverse transcription; PCR: polymerase chain reaction.

![Confirmation of DEmiRNAs\
**(A)** mmu-miR-32\* in SP^+^ LCSCs. **(B)** mmu-miR-466i-5p in SP^+^ LCSCs. **(C)** mmu-miR-669c in SP^+^ LCSCs. **(D)** mmu-miR-34c\* in SP^+^ LCSCs. **(E)** mmu-miR-122\* in SP^+^ LCSCs. **(F)** mmu-miR-541\* in SP^+^ LCSCs. **(G)** mmu-miR-106b\* in CD34^+^SCA1^+^ BMHSCs. **(H)** mmu-miR-144 in CD34^+^SCA1^+^ BMHSCs. **(I)** mmu-miR-669k\* in CD34^+^SCA1^+^ BMHSCs. **(J)** mmu-miR-142-3p in CD34^+^SCA1^+^ BMHSCs. **(K)** mmu-miR-210 in CD34^+^SCA1^+^ BMHSCs. **(L)** mmu-miR-223 in CD34^+^SCA1^+^ BMHSCs. \#: P\<0.05 when compared with control group. \*: P\<0.05 when compared with CTX group. DEmiRNAs: differentially expressed microRNAs; LCSCs: lung cancer stem cells; BMHSCs: bone marrow hematopoietic stem cells; CTX: cyclophosphamide; SHSB: Shuanghuang Shengbai. Quantitative real time-polymerase chain reaction was performed to confirm the expressions of these microRNAs. For all these tests, N=6.](oncotarget-08-62154-g003){#F3}

In addition, mmu-miR-106b\* (Figure [3G](#F3){ref-type="fig"}), mmu-miR-144 (Figure [3H](#F3){ref-type="fig"}) and mmu-miR-669k\* (Figure [3I](#F3){ref-type="fig"}) in CD34^+^SCA1^+^ BMHSCs were down-regulated after CTX treatment. However, these microRNAs were up-regulated after CTX+SHSB treatment. On the contrary, mmu-miR-142-3p (Figure [3J](#F3){ref-type="fig"}), mmu-miR-210 (Figure [3K](#F3){ref-type="fig"}) and mmu-miR-223 (Figure [3L](#F3){ref-type="fig"}) in CD34^+^SCA1^+^ BMHSCs were up-regulated after CTX treatment. These microRNAs were down-regulated after CTX+SHSB treatment. These results indicated that SHSB reversed the effects of CTX on microRNAs like mmu-miR-106b\*, mmu-miR-144, mmu-miR-669k\*, mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223 in CD34^+^SCA1^+^ BMHSCs.

DISCUSSION {#s3}
==========

CTX frequently causes myelosuppression \[[@R5]\], and SHSB granule can cure myelosuppression without promoting the development of lung cancer \[[@R11], [@R12]\]. However, its mechanism and therapeutic targets are still unclear.

In this study, CTX treatment strongly suppressed tumor growth (Figure [1A](#F1){ref-type="fig"}). CTX decreased SP^+^ LCSCs ratio (Figure [1G](#F1){ref-type="fig"}) and CD133^+^ LCSCs ratio (Figure [1I](#F1){ref-type="fig"}). Reportedly, alkylating units in the CTX-derived phosmoramide mustard in human can alkylate DNA \[[@R20]\], and CTX induces cell apoptosis \[[@R21], [@R22]\]. Our results were consistent with the suppressive effects of CTX on lung cancer \[[@R4]\]. These results also suggested that CTX might suppress lung cancer growth via decreasing SP^+^ LCSCs and CD133^+^ LCSCs.

More importantly, proliferation index of lung cancer cells (Figure [1E](#F1){ref-type="fig"}), SP^+^ LCSCs ratio (Figure [1G](#F1){ref-type="fig"}) and CD24^+^IGF1R^+^ LCSCs ratio (Figure [1H](#F1){ref-type="fig"}) in CTX+SHSB group were remarkably lower than that in control and CTX groups. These results agreed well with the inhibitory effects of SHSB on the transformation of lung cancer cells from G0/G1 phase to S phase \[[@R10]\]. Also, these results indicated that SHSB granule might suppress the growth of lung cancer via decreasing SP^+^ LCSCs.

In the present study, CTX remarkably reduced the number of WBCs (Figure [1B](#F1){ref-type="fig"}). This result was consistent with the fact that CTX could cause myelosuppression \[[@R5]\]. After CTX treatment, declines were found in the proliferation index of BMCs (4-d; Figure [1F](#F1){ref-type="fig"}) and CD34^+^SCA1^+^ BMHSCs ratio (Figure [1J](#F1){ref-type="fig"}). This suggested that CTX might cause myelosuppression via inhibiting the proliferation of CD34^+^SCA1^+^ BMHSCs. In contrast, SHSB granule completely reversed the decrease in WBCs (Figure [1B](#F1){ref-type="fig"}). This agreed well with the fact that SHSB could cure myelosuppression \[[@R10]-[@R12]\]. Especially, SHSB remarkably increased the proliferation index of BMCs (Figure [1F](#F1){ref-type="fig"}) and CD34^+^SCA1^+^ BMHSCs ratio (Figure [1J](#F1){ref-type="fig"}). As WBCs derived from BMHSCs, our results indicated that SHSB might increase WBCs via promoting the proliferation of CD34^+^SCA1^+^ BMHSCs.

As shown in qRT-PCR results, CTX enhanced the expression of mmu-miR-32\*, mmu-miR-466i-5p and mmu-miR-669c in SP^+^ LCSCs, and SHSB granule further strengthened their expression (Figure [3A--3C](#F3){ref-type="fig"}). Reportedly, miR-32 is located at 9q31.2 in a region of homozygous deletion in various types of cancer \[[@R23]\]. For instance, it promotes the growth, migration and invasion of colorectal carcinoma cells \[[@R24]\]. Currently, little is known about the role of miR-466i-5p in cancer development. Ionizing radiation can induce apoptosis in cochlea hair cells, and miR-466i-5p in HEI-OC1 cells is significantly up-regulated 12, 24 and 48 h after ionizing radiation \[[@R25]\]. MiR-669c is significantly down-regulated in mice with Bronchiolo-alveolar adenocarcinoma \[[@R26]\]. In this study, the up-regulations of miR-32\*, miR-466i-5p and mmu-miR-669c in SP^+^ LCSCs after CTX treatment were consistent with previous studies \[[@R23], [@R25], [@R26]\]. Besides, these microRNAs were further up-regulated after CTX+SHSB treatment. This indicated that SHSB might further inhibit SP^+^ LCSCs proliferation via enhancing the expressions of miR-32\*, miR-466i-5p and mmu-miR-669c.

Moreover, CTX significantly changed the expressions of mmu-miR-106b\* (down-regulation), mmu-miR-144 (down-regulation), mmu-miR-669k\* (down-regulation), mmu-miR-142-3p (up-regulation), mmu-miR-210 (up-regulation) and mmu-miR-223 (up-regulation) in CD34^+^SCA1^+^ BMHSCs (Figure [3G--3L](#F3){ref-type="fig"}). However, SHSB reversed the effects of CTX on these microRNAs (Figure [3G--3L](#F3){ref-type="fig"}). Among these microRNAs, little is known about the role of miR-106b\*, mmu-miR-144 and miR-669k\* in proliferation or differentiation of hematopoietic stem cells \[[@R27], [@R28]\]. In contrast, miR-142a-3p accelerates the formation and differentiation of hematopoietic stem cells \[[@R29]\]. MiR-210 level is increased in CD34^+^ cells in myelodysplastic syndromes, a disease caused by abnormal proliferation and differentiation of hematopoietic stem cells \[[@R30]\]. MiR-223 is preferentially expressed in bone marrow \[[@R31]\], and it induces human granulopoiesis \[[@R32]\]. Therefore, SHSB might enhance BMHSCs proliferation via up-regulating mmu-miR-106b\*, mmu-miR-144 and mmu-miR-669k\*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223.

MATERIALS AND METHODS {#s4}
=====================

Animals, cell line, and lung cancer models {#s4_1}
------------------------------------------

Nude mice are immune deficient, and tumor can be easily established in them. Therefore, four-week old male BALB/C nude mice weighted 20±2g were purchased from Shanghai Laboratory Animal Center of Chinese Academy of Sciences \[Batch Number: SCXK (Shanghai) 2007-0005\]. These mice were bred in the Specific-Pathogen-Free animal laboratory of Longhua Hospital (Shanghai, China) under a condition of 24-26^o^C, 65-70% humidity and free access to diet and water.

Lung adenocarcinoma is one of the main kinds of lung cancer, and A549 is a cell line of human lung adenocarcinoma. In this study, A549 was obtained from the Shanghai Cell Bank of Chinese Academy of Sciences. A549 cells were cultured in F12k medium supplemented with 10% fetal bovine serum (Gibco, NY, USA). Then, 0.2 ml 1×10^7^/ml A549 cells with high proliferating activity were inoculated into the oxters of nude mice. Lung cancer models were successfully constructed four weeks after inoculation.

Animal grouping and drug administration {#s4_2}
---------------------------------------

The constructed cancer models were randomly divided into three groups, including control group (N=36), CTX group (i.e. CTX group; N=36), and CTX + SHSB granule group (i.e. CTX+SHSB group; N=36). Since CTX could lead to obvious myelosuppression, we utilized CTX to treat lung cancer to establish a mice model of myelosuppression. CTX was generated from Jiangsu Hengrui Medicine Co., Ltd (Batch Number: H32020857). Before usage, 1 mg/ml CTX was freshly prepared using physiological saline. SHSB granule was obtained from the drug preparation center of Longhua Hospital (Batch Number: Z05170773). SHSB granule was dissolved in double-distilled H~2~O to generate a 2 g/ml SHSB solution. Nude mice in control group were intraperitoneally injected with physiological saline (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Nude mice in CTX group were intraperitoneally injected with CTX (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Nude mice in CTX+SHSB group were intraperitoneally injected with CTX (100 mg/kg/d) for three days, and these mice also took SHSB (40 g/kg/d) via gastroenteric irrigation for 10 days. Intraperitoneal injection and gastroenteric irrigation were started at the same day for all mice. All the animal experiments were approved by the Animal Ethics Committee of Shanghai Longhua Hospital, China.

General blood indexes and tumor mass {#s4_3}
------------------------------------

Eyeball was removed, and peripheral blood was taken from mice 4, 6, 8 or 10 days after intraperitoneal injection. WBCs, red blood cells and platelets were counted using an automatic blood cell analyzer (DxH 800™; Beckman Coulter Inc., Miami, FL, USA). Thereafter, mice were sacrificed by cutting off their neck under anesthesia. Xenograft tumors were obtained and weighted under a sterile and RNAase-free condition.

Generation of lung cancer cells and BMCs {#s4_4}
----------------------------------------

Lung cancer cells were generated from xenograft tumor (4-d, 6-d, 8-d and 10-d) after trypsin digestion. The femur and tibia were taken from the sacrificed mice (4-d, 6-d, 8-d and 10-d) and sterilized using 75% alcohol. BMCs were obtained after splitting and opening the femur and tibia. Then, 2 ml hemolysin was added into BMCs suspension to damage red blood cells. The suspension was centrifuged at 2000 rpm for 15 min.

Determination of cell cycle and proliferation index {#s4_5}
---------------------------------------------------

Lung cancer cells and BMCs were immobilized at 4°C for 10 h using 70% and absolute ethyl alcohol, respectively. Cells were washed with phosphate buffer solution. RNase A was added (final concentration: 50 μg/ml) to digest RNA at 37°C for 30 min. Propidium iodide solution was added (final concentration: 65 μg/ml) to stain cells for 30 min. Then, FACSCalibur™ Cell Sorting system (BD Biosciences; Franklin Lakes, NJ, USA) was utilized to perform flow cytometry to determine cell cycle. Based on cell cycle information, proliferation index was calculated using the following formula:$$\text{Proliferation\ index} = \frac{S + G_{2}/M}{G_{0}/G_{1} + S + G_{2}/M} \times 100\%$$

In this formula, G~0~ /G~1~, S and G~2~ /M represent the relative numbers of cells in phase G~0~ /G~1~, S and G~2~ /M, respectively.

Ratio of stem cells {#s4_6}
-------------------

For each sample of lung cancer cells (500 μl, 2×10^6^/ml), 10 μl Heochst 33342/Propidium iodide solution was added to mark SP^+^ LCSCs; 10 μl Anti-CD24 labeled with allophycocyanin and 20 μl Anti-IGF1R labeled with phycoerythrin were added to mark CD24^+^IGF1R^+^ LCSCs; 20 μl Anti-CD133 labeled with allophycocyanin was added to mark CD133^+^ LCSCs.

For each BMCs sample (500 μl, 2×10^6^/ml), 20 μl Anti-CD34 labeled with allophycocyanin and 20 μl Anti-SCA1 labeled with phycoerythrin were added to mark CD34^+^SCA1^+^ BMHSCs. Flow cytometry was used to detect the ratios of these stem cells.

MicroRNA microarray analysis {#s4_7}
----------------------------

Flow cytometry was used to isolate SP^+^ LCSCs and CD34^+^SCA1^+^ BMHSCs from lung cancer cells (8-d) and BMCs (6-d), respectively. For each sample, total RNA was isolated using Trizol Reagent (Invitrogen; CA, USA), and microRNA was purified using miRNeasy mini kit (Qiagen; Valencia, CA, USA). RNA quantity and quality were determined using NanoDrop spectrophotometer (ND-1000; Nano-Drop Technologies; DE, USA). Thereafter, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon; Vedbaek, Denmark) was utilized to label 1 mg microRNA to miRCURY™ LNA Array (version: 16.0).

Microarray data were normalized using the Quantile method. Differentially expressed microRNAs (DEmiRNAs) between groups were identified via Volcano Plot filtering \[criteria: Fold change ≥1.5 and P≤0.05\] and analysis of variance (ANOVA; criterion: P≤0.05). Moreover, hierarchical clustering was conducted using the MeV software (v4.6; the institute for genomic research; <http://www.tm4.org/mev.html>) to determine the specificity of DEmiRNAs between groups.

qRT-PCR {#s4_8}
-------

A total of 12 DEmiRNAs were randomly selected, and their relative levels were detected. Total RNA was isolated from SP^+^ LCSCs (4-d, 6-d, 8-d and 10-d) and CD34^+^SCA1^+^ BMHSCs (4-d, 6-d, 8-d and 10-d) using Trizol Reagent (Invitrogen). Reverse transcription was conducted in a 20 μl reaction system (condition: 37°C for 15 min and then 85°C for 5 s) using PrimeScript RT reagent kit (TaKaRa Biotechnology Co. Ltd.; Dalian, China). Thereafter, RT-PCR was performed in a 20 μl reaction system \[condition: 95°C for 5 min, 40 cycle (95°C for 10 s, 60°C for 20 s, 72°C for 20 s, and 79°C for 20 s)\] using the SYBR Premix Ex Taq kit (TaKaRa) and a PCR instrument (Rotor Gene 3000; Corbett Research; Sydney, Australia). Relative levels of these microRNAs were calculated using 2^-∆∆CT^ method and U6 levels.

Statistical analysis {#s4_9}
--------------------

All data were shown in a "mean ± standard deviation" manner and analyzed using Statistical Product and Service Solutions (SPSS; version: 18.0) software. Differences between groups were determined using one-way ANOVA method. Least-Significant-Difference test was utilized under a condition of equal variance. Otherwise, Dunnett's T3 method was used to adjust results. The threshold for statistical difference was set as P\<0.05.

CONCLUSION {#s5}
==========

To sum up, SHSB granule might cure CTX-induced myelosuppression and increase WBCs via enhancing CD34^+^SCA1^+^ BMHSCs proliferation (SHSB granule up-regulated the expressions of mmu-miR-106b\*, mmu-miR-144 and mmu-miR-669k\*, as well as down-regulated the expressions of mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223 in CD34^+^SCA1^+^ BMHSCs). Besides, SHSB granule might also suppress lung cancer progression via inhibiting SP^+^ LCSCs proliferation (SHSB granule up-regulated miR-32\*, miR-466i-5p and mmu-miR-669c in SP^+^ LCSCs). These findings might help us to better understand the mechanism of SHSB in curing myelosuppression and blocking lung cancer development. Our results might also provide potential therapeutic targets for treating CTX-caused myelosuppression in patients with lung cancer.

Limitation {#s5_1}
----------

In the present study, microRNA profiling was only determined in SP^+^ LCSCs (8-d) and CD34^+^SCA1^+^ BMHSCs (6-d). A time-course microRNA profiling analysis might provide more information. Only the change patterns of 12 microRNAs were detected by using qRT-PCR. Much more microRNAs will be selected to perform qRT-PCR in our future study.

SUPPLEMENTARY MATERIALS FIGURE {#s6}
==============================
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